AL002 Falls Short in Phase 2 INVOKE-2 Trial of Early Alzheimer Disease

Published Date: 28 Nov 2024

AL002 did not meet the primary endpoint of slowing Alzheimer's clinical progression, as measured by the Clinical Dementia Rating Sum of Boxes and showed no treatment effects on secondary clinical and functional endpoints.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

2.

New drug resistance mechanism in melanoma leptomeningeal disease revealed by study.

3.

Research finds stark disparities in treatment and survival time for people with pancreatic cancer

4.

Tumor characteristics found to differ for melanomas in children, teens and young adults

5.

Relationship-building key to addressing oncologist shortages in rural care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot